On March 24, 2026, Incubate and the National Security Commission on Emerging Biotechnology (NSCEB) convened a Capitol Hill roundtable with venture capital investors, NSCEB leaders, and congressional staff to discuss U.S. biotech competitiveness.1
The event featured key participants including NSCEB Vice Chair Dr. Michelle Rozo, Executive Director Caitlin Frazer, and investors from firms like Forge Life Science Partners, Pfizer PAVE, and Bessemer Venture Partners.1
Discussions covered NSCEB's priorities for reducing R&D risk, drug pricing policies like 'Most Favored Nation' international reference pricing, FDA regulatory uncertainty, and intellectual property protections.1
John Stanford, Incubate's executive director, emphasized that policies importing price controls or weakening IP undermine U.S. biotech leadership and investment.1
NSCEB Vice Chair Michelle Rozo highlighted the need for regulatory reforms and government investment to mobilize private capital in biotech.1
Incubate is a 501(c)(4) organization advocating for venture capital's role in life sciences innovation and educating policymakers.15
Sources:
1. https://www.globenewswire.com/news-release/2026/03/24/3261644/0/en/Incubate-and-the-National-Security-Commission-on-Emerging-Biotechnology-Convene-Capitol-Hill-Roundtable-on-U-S-Biotech-Competitiveness.html